Statements (31)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
gptkb:drug
small molecule |
| gptkbp:approvedBy |
gptkb:FDA
2018 chronic immune thrombocytopenia |
| gptkbp:ATCCode |
L04AA41
|
| gptkbp:brand |
Tavalisse
|
| gptkbp:CASNumber |
873857-62-6
|
| gptkbp:developedBy |
gptkb:Rigel_Pharmaceuticals
|
| gptkbp:eliminationHalfLife |
15 hours
|
| gptkbp:hasMolecularFormula |
C23H26FN6O5
|
| gptkbp:hasSMILES |
CCOC(=O)COc1ccc(cc1)Nc2ncnc3[nH]c(=O)n(c23)C4CCN(CC4)C(=O)CF
|
| gptkbp:hasUNII |
4F1Q995K2V
|
| https://www.w3.org/2000/01/rdf-schema#label |
fostamatinib
|
| gptkbp:legalStatus |
prescription only
|
| gptkbp:mechanismOfAction |
SYK inhibitor
|
| gptkbp:metabolism |
gptkb:CYP3A4
|
| gptkbp:molecularWeight |
492.49 g/mol
|
| gptkbp:pregnancyCategory |
not recommended
|
| gptkbp:PubChem_CID |
gptkb:DB12010
gptkb:CHEMBL2103888 11671467 |
| gptkbp:routeOfAdministration |
oral
|
| gptkbp:sideEffect |
nausea
diarrhea hypertension liver enzyme elevation |
| gptkbp:bfsParent |
gptkb:Syk
gptkb:Syk_kinase gptkb:Rigel_Pharmaceuticals |
| gptkbp:bfsLayer |
8
|